Cambridge, UK and Indianapolis, US - 7 September 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company" or the "Group"), (ACPH.NX) announces that it will hold a General Meeting of shareholders on 25 September 2018 at 10.00 a.m. BST at the offices of Stephenson Harwood LLP, 1 Finsbury Circus London EC4M 7SH, in order to consider and vote on Proposed Authorities to Allot Shares and Disapply Pre-emption Rights.
The Notice of General Meeting and Circular to Shareholders as well as the proxy form are available on the Investors` section of the Acacia Pharma website at www.acaciapharma.com/investors/shareholder-meetings
Contacts
| Acacia Pharma Group plc | +44 1223 919760 |
| Citigate Dewe Rogerson | +44 20 7638 9571 |
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Group`s lead project, BARHEMSYS(TM) (amisulpride injection) for post-operative nausea & vomiting (PONV) has successfully completed Phase 3 clinical studies and New Drug Application (NDA) is under review by the US Food & Drug Administration (FDA) for marketing approval. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com
About BARHEMSYS(TM)
BARHEMSYS comprises a low dose intravenous formulation of the marketed dopamine antagonist amisulpride. The NDA submission for BARHEMSYS, including data from four positive Phase 3 studies and more than 3,300 surgical patients and healthy volunteers, is currently under review by the US FDA. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of 5 October 2018 to complete its review.
About PONV
PONV is a common complication of surgery, occurring in approximately 30% of surgical patients and up to 80% of high-risk patients. It is associated with the use of anaesthetic gases and opioid pain-killers and is particularly common following gynaecological, abdominal, breast, eye and ear operations, especially those lasting an hour or more.